Table 2.

Regression analyses of weight-for-age z-scores (WAZ) at birth and their evolution over time by exposure to antiretroviral drugs (ARV).

	Univariable linear regression of WAZ at birth N=575		Multivariable linear regression of WAZ at birth* N=359
	Difference in WAZ (95%CI**)	P-value	Difference in WAZ (95%CI**)	P-value
ARVs in the first trimester	−0.30 (−0.55 to −0.06)	0.02	−0.52 (−0.99 to −0.04)	0.02
No ARVs during pregnancy	−0.20 (−0.43 to 0.02)	0.07	0.30 (−0.08 to 0.69)	0.12
ARVs in the second or third trimester	0 (reference)	-	0 (reference)	-

	Univariable mixed-effects regression of WAZ over time (N=582)		Multivariable mixed-effects regression of WAZ over time* (N=358)
	Difference in WAZ (95%CI**)	P-value	Difference in WAZ (95%CI**)	P-value
ARVs in the first trimester	−0.17 (−0.40 to 0.06)	0.15	−0.22 (−0.47 to 0.04)	0.10
No ARVs during pregnancy	−0.19 (−0.40 to 0.01)	0.07	−0.01 (−0.34 to 0.36)	0.96
ARVs in the second or third trimester	0 (reference)	-	0 (reference)	-

^**CI, confidence interval; ARV, antiretroviral drugs; WAZ, weight-for-age z-score

^*Adjusted for mother's age (younger than 25 years or older), CD4 cell count (square root transformed), viral load (undetectable or detectable), year of birth, and family income. N=358 children